Menotropin (human menopausal gonadotropin, hMG) is indicated for controlled ovarian stimulation in women undergoing assisted reproductive technologies such as IVF/ICSI, and for ovulation induction in anovulatory infertility. It is also used in men with hypogonadotropic hypogonadism to stimulate spermatogenesis. Its key advantage is the combined FSH and LH activity, which supports both follicular growth and steroidogenesis, providing a more physiological stimulation compared to FSH-only products. This is particularly beneficial in patients with low LH levels or poor ovarian response. Injectable administration allows precise dose titration and individualized protocols based on patient response. In fertility practice, menotropin is valued for its ability to improve follicular maturation, optimize hormonal balance, and enhance clinical pregnancy outcomes in selected patient groups.